Edition:
United Kingdom

Bergenbio ASA (BGBIO.OL)

BGBIO.OL on Oslo Stock Exchange

25.90NOK
3:19pm GMT
Change (% chg)

kr1.90 (+7.92%)
Prev Close
kr24.00
Open
kr24.70
Day's High
kr26.00
Day's Low
kr24.50
Volume
17,459
Avg. Vol
47,351
52-wk High
kr54.80
52-wk Low
kr23.10

Latest Key Developments (Source: Significant Developments)

Bergenbio: Grant From Research Council Of Norway Under BIA Programme
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Bergenbio ASA ::BERGENBIO ANNOUNCES THE ALLOCATION OF RESEARCH AND DEVELOPMENT GRANT OF UP TO NOK 12M AWARDED.AWARD OF A GRANT FROM RESEARCH COUNCIL OF NORWAY UNDER USER-DRIVEN INNOVATION AREA (BIA) PROGRAMME..PROCEEDS WILL BE USED TO FUND RESEARCH INTO AXL'S ROLE IN FIBROTIC DISEASES.UP TO NOK 12 MILLION WILL BE DISBURSED OVER A THREE-YEAR PERIOD STARTING IN 2019.  Full Article

Bergenbio Announces Start Of Phase I Trial Evaluating BGB149
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Bergenbio ASA ::BERGENBIO ANNOUNCES START OF PHASE I TRIAL EVALUATING FIRST-IN-CLASS.PHASE I STUDY WILL INVESTIGATE SAFETY AND PHARMACOKINETICS IN HEALTHY VOLUNTEERS.BERGENBIO - EXPECTS RESULTS FROM PHASE I TRIAL IN 2019, TO ANNOUNCING BGB149'S FURTHER CLINICAL DEVELOPMENT STRATEGY IN COMING MONTHS.ANNOUNCES START OF PHASE I TRIAL EVALUATING FIRST-IN-CLASS ANTI-AXL ANTIBODY BGB149.  Full Article

Bergenbio Q3 Net Loss Widens To NOK 37.7 Million
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Bergenbio ASA ::: RESULTS FOR THE THIRD QUARTER 2018.TOTAL OPERATING EXPENSES FOR Q3 WERE NOK 38.1 MILLION (NOK 36.6 MILLION).Q3 NET LOSS NOK 37.7 MILLION VERSUS LOSS NOK 35.4 MILLION YEAR AGO.  Full Article

BerGenBio Q2 Net Loss Widens To NOK 49.2 Million
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - BerGenBio ASA ::Q2 OPERATING LOSS NOK 50.7 MILLION VERSUS LOSS NOK 33.8 MILLION YEAR AGO.Q2 NET LOSS NOK 49.2 MILLION VERSUS LOSS NOK 34.1 MILLION YEAR AGO.  Full Article

Bergenbio Q1 Operating Loss Narrows To NOK 54.8 Million
Tuesday, 15 May 2018 

May 15 (Reuters) - Bergenbio ASA ::Q1 OPERATING LOSS NOK 54.8 MILLION VERSUS LOSS NOK 65.8 MILLION YEAR AGO.Q1 NET LOSS NOK 53.8 MILLION VERSUS LOSS NOK 65.1 MILLION YEAR AGO.  Full Article

BerGenBio: Promising Data Highlighting Selective AXL Inhibitor
Wednesday, 18 Apr 2018 

April 18 (Reuters) - BERGENBIO ASA ::BERGENBIO: PROMISING DATA HIGHLIGHTING SELECTIVE AXL INHIBITOR.DATA HIGHLIGHT BEMCENTINIB'S POTENTIAL TO REVERSE TUMOUR IMMUNE SUPPRESSION AND ENHANCE IMMUNE CHECKPOINT INHIBITOR EFFICACY.  Full Article

Bergenbio: Promising Pre Clinical Data Supporting Bergenbio's Pipeline To Be Published
Friday, 13 Apr 2018 

April 13 (Reuters) - BERGENBIO ASA ::PROMISING PRE-CLINICAL DATA SUPPORTING BERGENBIO'S PIPELINE TO BE PUBLISHED AND PRESENTED AT UPCOMING LEADING CONFERENCES.  Full Article

Bergenbio ‍Gets Approval From FDA
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Bergenbio Asa ::‍GAINED REQUIRED APPROVALS FROM US FDA PRIOR TO STARTING STUDY WITH BGB324​.‍IS IN DISCUSSIONS WITH REK IN BERGEN AND NORWEGIAN BOARD OF HEALTH TO GAIN APPROVAL TO CONDUCT BGBC004 STUDY IN US​.  Full Article

Bergenbio Q3 operating loss widens to NOK 36.6 mln
Friday, 17 Nov 2017 

Nov 17 (Reuters) - BERGENBIO ASA ::Q3 REVENUE NOK 36.6 MILLION VERSUS NOK 16.3 MILLION YEAR AGO.Q3 OPERATING LOSS NOK 36.6 MILLION VERSUS LOSS NOK 16.3 MILLION YEAR AGO.  Full Article

Bergenbio Q3 operating loss widens to NOK 36.6 million
Friday, 17 Nov 2017 

Nov 17 (Reuters) - BERGENBIO ASA :Q3 OPERATING EXPENSES NOK 36.6 MILLION VERSUS NOK 16.3 MILLION YEAR AGO.Q3 OPERATING LOSS NOK 36.6 MILLION VERSUS LOSS NOK 16.3 MILLION YEAR AGO.  Full Article